Back to Search
Start Over
Clock genes and body composition in patients with schizophrenia under treatment with antipsychotic drugs.
- Source :
-
Schizophrenia research [Schizophr Res] 2011 Feb; Vol. 125 (2-3), pp. 187-93. Date of Electronic Publication: 2010 Nov 03. - Publication Year :
- 2011
-
Abstract
- Context: In the healthy population, several pathways are known to exert an effect on basal metabolic factors. Previous studies have found associations between single nucleotide polymorphisms in clock genes or downstream hormone receptors such as the leptin receptor (LEPR) or glucocorticoid receptor (NR3C1) and obesity in the healthy population, but this association remains to be examined in patients with schizophrenia treated with antipsychotics.<br />Objective: To assess anthropomorphic parameters in patients taking second-generation antipsychotics (SGA) as a function of nine polymorphisms in three core genes of the clock pathway, and two genes of downstream hormone receptors.<br />Methods: Clinical parameters were evaluated in 261 patients with schizophrenia spectrum disorder. Polymorphisms in LEPR, MC3R, NR3C1, PER2 and SDC3 were genotyped. In order to control for multiple testing, permutation tests were used to generate corrected empirical p-values using the Max(T) procedure in PLINK.<br />Results: A significant effect of the rs6196 polymorphism in the NR3C1 on weight (β=-4.18; SE=2.02; p=0.018), BMI (β=-1.88; SE=0.64; p=0.004), waist (β=-5.77; SE=1.75; p=0.001) and waist/hip ratio (β=-0.03; SE=0.012; p=0.009) was found. Permutation tests confirmed the findings for BMI (p=0.037) and waist (p=0.024). Carriers of the G allele consistently displayed better parameters than patients with the wild type allele. A weak effect of rs4949184 in SDC3 on BMI was found, but this did not sustain permutation testing (β=-1.27; SE=0.58; p=0.030, p=0.270 after permutations).<br />Conclusion: Variations in genes implicated in circadian regulation or its related downstream pathways may be important in the regulation of antropomorphic parameters in patients with schizophrenia during long-term treatment with SGA.<br /> (Copyright © 2010 Elsevier B.V. All rights reserved.)
- Subjects :
- Adult
Age Factors
Amisulpride
Anthropometry
Aripiprazole
Benzodiazepines adverse effects
Benzodiazepines therapeutic use
Body Mass Index
Clozapine adverse effects
Clozapine therapeutic use
Dibenzothiazepines adverse effects
Dibenzothiazepines therapeutic use
Drug Therapy, Combination
Female
Genetic Association Studies
Genetic Carrier Screening
Humans
Long-Term Care
Male
Middle Aged
Mutation, Missense
Olanzapine
Period Circadian Proteins genetics
Piperazines adverse effects
Piperazines therapeutic use
Quetiapine Fumarate
Quinolones adverse effects
Quinolones therapeutic use
Receptor, Melanocortin, Type 3 genetics
Receptors, Glucocorticoid genetics
Receptors, Leptin genetics
Risperidone adverse effects
Risperidone therapeutic use
Sex Factors
Sulpiride adverse effects
Sulpiride analogs & derivatives
Sulpiride therapeutic use
Syndecan-3 genetics
Alleles
Antipsychotic Agents adverse effects
Antipsychotic Agents therapeutic use
Body Composition drug effects
CLOCK Proteins genetics
Genotype
Polymorphism, Single Nucleotide genetics
Psychotic Disorders drug therapy
Psychotic Disorders genetics
Schizophrenia drug therapy
Schizophrenia genetics
Subjects
Details
- Language :
- English
- ISSN :
- 1573-2509
- Volume :
- 125
- Issue :
- 2-3
- Database :
- MEDLINE
- Journal :
- Schizophrenia research
- Publication Type :
- Academic Journal
- Accession number :
- 21050724
- Full Text :
- https://doi.org/10.1016/j.schres.2010.10.008